ArticleEuropean thyroid journal2026
Estimation of the delay for resumption of breastfeeding after 131-iodine therapy by milk radioactivity measurement.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractGuidelines recommend stopping breastfeeding before radioactive iodine (131I) therapy, yet the optimal timing for safe resumption remains unclear. We report a detailed dosimetric case study of a 29-year-old woman treated with 3,700 MBq 131I for papillary thyroid carcinoma who wished to resume breastfeeding. Weekly breast milk samples were analyzed using calibrated gamma counting until radioactivity fell below a conservative safety threshold. Results showed substantial iodine excretion in milk (∼15% of administered activity) with biphasic clearance. Estimated infant radiation exposure varied dramatically depending on resumption timing, ranging from 0.62 to 688 mSv. A strict activity-based threshold suggested delaying breastfeeding for 51 days, whereas a dosimetric approach limiting infant exposure to 1 mSv supported resumption as early as 9-10 days post-therapy. These findings highlight the limitations of fixed recommendations and support an individualized, measurement-based strategy to optimize mother and child safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.